Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines

Lung Cancer

Volumn 73, Issue 1, 2011, Pages 1-10

  de Marinis, Filippo ^a   Rossi, Antonio ^b   Di Maio, Massimo ^a   Ricciardi, Serena ^a   Gridelli, Cesare ^c  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

AIOT; Chemotherapy; EGFR; Guidelines; Non small cell lung cancer; Targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADVANCED CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COMORBIDITY; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MEDLINE; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MUTATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79957730176     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.02.022     Document Type: Review

References (88)

1. Agency for Healthcare Policy Research (AHCPR) System US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research Acute pain management: operative or medical procedures and trauma 1992, Agency for Health Care Policy and Research Publications, Rockville, MD.
2. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311:899-909.
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
4. Kelly K., Crowley J., Bunn P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
5. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
6. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005, 47:69-80.
7. Douillard J.Y., Laporte S., Fossella F., Georgoulias V., Pujol J.L., Kubota K., et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007, 2:939-946.
8. Grossi F., Aita M., Defferrari C., Rosetti F., Brianti A., Fasola G., et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009, 14:497-510.
9. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
10. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
11. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
12. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
13. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234. [Erratum in: J Clin Oncol 2009;27:2415].
14. Crinò L., Dansing E., Garrido P., Griesinger F., Laskin J., Pavlakis N., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small cell lung cancer (SAiL MO19390): a phase 4 study. Lancet Oncol 2010, 11:733-740.
15. Rossi G., Pelosi G., Graziano P., Barbareschi M., Papotti M. A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol 2009, 17:206-218.
16. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
17. Lynch T.J., Patel T., Dreisbach L., McCleod M., Heim W.J., Hermann R.C., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
18. Socinski M.A., Schell M.J., Peterman A., Bakri K., Yates S., Gitten R., et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002, 20:1335-1343.
19. Brodowicz D., Krzakowski M., Zwitter M., Tzekova V., Ramlau R., Ghilezan N., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006, 52:155-163.
20. von Plessen C., Bergman B., Andresen O., Bremnes R.M., Sundstrom S., Gilleryd M., et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006, 95:966-973.
21. Park J.O., Kim S.W., Ahn J.S., Suh C., Lee J.S., Jang J.S., et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol 2007, 25:5233-5239.
22. Klastersky J., Sculier J.P., Lacroix H., Dabouis G., Bureau G., Libert P., et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 1990, 8:1556-1562.
23. Jelić S., Mitrović L., Radosavljević D., Elezar E., Babović N., Kovcin V., et al. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer 2001, 34:1-13.
24. Bissett D., Nicolson M., Falk S., Dunlop D., Stares N., Loh E. Randomized phase II study of tirapazamine with either cisplatin or carboplatin in advanced NSCLC. Proc Am Soc Clin Oncol 2001, 20:346a. [abstr. 1381].
25. Rosell R., Gatzemeier U., Betticher D.C., Keppler U., Macha H.N., Pirker R., et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002, 13:1539-1549.
26. Zatloukal P., Petruzelka L., Zemanová M., Kolek V., Skricková J., Pesek M., et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage IIIB and IV non-small cell lung cancer (NSCLC): a phase III randomized trial. Lung Cancer 2003, 41:321-331.
27. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations vs vinorelbine plus cisplatin for advanced non-small cell lung cancer: The TAX 326 Study Group. J Clin Oncol 2003, 21:3016-3024.
28. Mazzanti P., Massacesi C., Rocchi M.B., Mattioli R., Lippe P., Trivisonne R., et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Lung Cancer 2003, 41:81-89.
29. Paccagnella A., Favaretto A., Oniga F., Barbieri F., Ceresoli G., Torri W., et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non-small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004, 43:83-91.
30. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:3852-3859.
31. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
32. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
33. Lee J.S., Park K., Kim S.W., Lee D.H., Kim H.T., Han J.Y., et al. A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009, 4(Suppl. 1):S283-S284. [abstr PRS.4].
34. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
35. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
36. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
37. Zhou C., Wung Y.I., Chen G., Feng J., Liu X., Wang C., et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in Chinese advanced non-small-cell lung cancer patients with EGFR activating mutations. Presented at European Society of Medical Oncology meeting 2010, [abstr LBA13].
38. Gridelli C., Ciardiello F., Feld R., Butts C.A., Gebbia V., Genestreti G., et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial. J Clin Oncol 2010, 28(15S):540s. [abstr 7508].
39. Soon Y.Y., Stockler M.R., Askie L.M., Boyer M.J. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009, 27:3277-3283.
40. Fidias P.M., Dakhil S.R., Lyss A.P., Loesch D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
41. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
42. Elderly Lung Cancer Vinorelbine Italian Study Group Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1991, 91:66-72.
43. Kudoh S., Takeda K., Nakagawa K., Takada M., Katakami N., Matsui K., et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG 9904). J Clin Oncol 2006, 24:3657-3663.
44. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000, 18:2529-2536.
45. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95:362-372.
46. Gridelli C., Aapro M., Ardizzoni A., Balducci L., De Marinis F., Kelly K., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005, 23:3125-3137.
47. Rossi A., Gridelli C. Chemotherapy of advanced non-small cell lung cancer in elderly patients. Ann Oncol 2006, 17(Suppl. 2):ii58-ii60.
48. Quoix E.A., Oster J., Westeel V., Pichon E., Zalcman G., Baudrin L., et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15S):5s. [abstr 2].
49. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
50. Jiroutek M., Johnson D., Blum R., Bonomi P., Chang A., Ettinger D., et al. Prognostic factors in advanced non-small-cell lung cancer: analysis of Eastern Cooperative Oncology Group trials from 1981-1992. Proc Am Soc Clin Oncol 1998, 17:461. [abstr 1774].
51. Gridelli C., Ardizzoni A., Le Chevalier T., Manegold C., Perrone F., Thatcher N., et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004, 15:419-426.
52. NSCLC Meta-analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625.
53. Anderson H., Hopwood P., Stephens R.J., Thatcher N., Cottier B., Nicholson M., et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. Br J Cancer 2000, 83:447-453.
54. Ranson M., Davidson N., Nicolson M., Falk S., Carmichael J., Lopez P., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000, 92:1074-1080.
55. Roszkowski K., Pluzanska A., Krzakowski M., Smith A.P., Saigi E., Aasebo U., et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000, 27:145-157.
56. Lilenbaum R.C., Herndon J.E., List M.A., Desch C., Watson D.M., Miller A.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005, 23:190-196.
57. Lilenbaum R., Axelrod R., Thomas S., Dowlati A., Seigel L., Albert D., et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008, 26:863-869.
58. Goss G., Ferry D., Wierzbicki R., Laurie S.A., Thompson J., Biesma B., et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009, 27:2253-2260.
59. Lee S., Rudd R., Khan I., Upadhyay S., Lewanski C.R., Falk S., et al. Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol 2010, 28(15S):540s. [abstr 7504].
60. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2085-2103.
61. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000, 18:2354-2362.
62. Gridelli C., Gallo C., Di Maio M., Barletta E., Illiano A., Maione P., et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004, 91:1996-2004.
63. Gervais R., Ducolone A., Breton J.L., Braun D., Lebeau B., Vaylet F., et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2005, 16:90-96.
64. Schuette W., Nagel S., Blankenburg T., Lautenschlaeger C., Hans K., Schmidt E.W., et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005, 23:8389-8395.
65. Lai C.L., Tsai C.M., Chiu C.H., Wang G.S., Su W.J., Chen Y.M., et al. Phase II randomized trial of tri-weekly versus day 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol 2005, 35:700-706.
66. Camps C., Massuti B., Jiménez A., Maestu I., Gómez R.G., Isla D., et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006, 17:467-472.
67. Di Maio M., Perrone F., Chiodini P., Gallo C., Camps C., Schuette W., et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:1377-1382.
68. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
69. Takeda K., Negoro S., Tamura T., Nishiwaki Y., Kudoh S., Yokota S., et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 2009, 20:835-841.
70. Georgoulias V., Kouroussis C., Agelidou A., Boukovinas I., Palamidas P., Stavrinidis E., et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 2004, 91:482-488.
71. Georgoulias V., Agelidou A., Syrigos K., Rapti A., Agelidou M., Nikolakopoulos J., et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br J Cancer 2005, 93:763-769.
72. Wachters F.M., Groen H.J., Biesma B., Schramel F.M., Postmus P.E., Stigt J.A., et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 2005, 92:15-20.
73. Pectasides D., Pectasides M., Farmakis D., Kostopoulou V., Nikolaou M., Gaglia A., et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 2005, 16:294-299.
74. Gebbia V., Gridelli C., Verusio C., Frontini L., Aitini E., Daniele B., et al. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Lung Cancer 2009, 63:251-258.
75. Smit E.F., Burgers S.A., Biesma B., Smit H.J., Eppinga P., Dingemans A.M., et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non small-cell lung cancer. J Clin Oncol 2009, 27:2038-2045.
76. Di Maio M., Chiodini P., Georgoulias V., Hatzidaki D., Takeda K., Wachters F.M., et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:1836-1843.
77. Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer. Clinicaltrials.gov Identifier: ctgov:NCT00065182.
78. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
79. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
80. Zhu C.Q., da Cunha Santos G., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
81. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer). Lancet 2005, 366:1527-1537.
82. Shepherd F.A., Douillard J., Fukuoka M., Saijo N., Kim S., Cufer T., et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): meta-analysis from four clinical trials. J Clin Oncol 2009, 27(15S):409s. [abstr 8011].
83. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-smallcell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
84. Lee D., Kim S., Park K., Kim J., Lee J., Shin S., et al. A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy. J Clin Oncol 2008, 26:430s. [abstr 8025].
85. Cufer T., Vrdoljak E., Gaafar R., Erensoy I., Pemberton K. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006, 17:401-409.
86. Maruyama R., Nishiwaki Y., Tamura T., Yamamoto N., Tsuboi M., Nakagawa K., et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008, 26:4244-4252.
87. Vamvakas L., Agelaki S., Kentepozidis N.K., Karampeazis A., Pallis A.G., Christophyllakis C., et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol 2010, 28(15S):543s. [abstr 7519].
88. Ciuleanu T., Stelmakh L., Cicenas S., Esteban E. Erlotinib versus docetaxel or pemetrexed as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) and poor prognosis: efficacy and safety results from the phase III TITAN study. Presented at Chicago Thoracic Multidisciplinary Symposium 2010, [abstr LBOA5].